Epizyme reported $186.84M in Current Assets for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Assets Change
Agios Pharmaceuticals AGIO:US $ 870.01M 105.14M
Amarin AMRN:US $ 719.12M 53.5M
Amgen AMGN:US $ 19322M 802M
Avrobio Inc AVRO:US 142.08M 28.84M
Biogen BIIB:US $ 9740.9M 1825M
Bluebird Bio BLUE:US $ 167.46M 87.46M
Cerulean Pharma CERU:US $ 47.82M 7.48M
Daiichi Sankyo 4568:JP Y 1367130M 21859M
Eisai 4523:JP Y 620947M 19659M
Epizyme EPZM:US $ 186.84M 41.87M
Exelixis EXEL:US $ 1851.64M 8.9M
Gilead Sciences GILD:US $ 13705M 1076M
GlaxoSmithKline GSK:LN 54.19B 25.2B
Glaxosmithkline GSK:US $ 54188M 25200M
Karyopharm Therapeutics KPTI:US $ 242.45M 34.09M
Macrogenics MGNX:US $ 167.63M 50.57M
Mirati Therapeutics MRTX:US $ 1202.93M 140.19M
Novartis NOVN:VX 38.14B 906M
Novartis NVS:US $ 38142M 906M
Regeneron Pharmaceuticals REGN:US $ 15529.9M 1223.9M
Seattle Genetics SGEN:US $ 2778.66M 7.4M
Spectrum Pharmaceuticals SPPI:US $ 73.58M 19.6M
Vertex Pharmaceuticals VRTX:US $ 11503.5M 1142.2M
Xencor XNCR:US $ 585.94M 79.97M